12th Congress of the European Hematology ... - Haematologica

Bortezomib 1.3 mg/m 2 days 1,4,8,11; Doxorubicin 20 mg/m 2 i.v. days 1,4
or Pegilated Lyposomal Doxorubicin 30 mg/m 2 i.v. day 1; and Dexamethasone
40 mg p.o, days 1,2,3,4. Each cycle was repeated every month.
Results. Patients received a median number of 4 cycles (range 1-8). Median
number of prior therapies was 2 (range 1-7) and median time from
diagnosis was 31 months (range 2-181 months): 27% patients received
prior Bortezomib based-regimens, 75% prior Thalidomide based-regimens
and 58% prior transplantation. Forty-three patients (67%) achieved
at least partial response (PR) including 16 patients (25%) who showed
at least very good partial response (VGPR) and 6 patients (9%) who
achieved a complete response (CR). In patients who received PAD as 2nd
line treatment, the PR and VGPR rates were 80% and 27%, respectively;
CR was reported in 13%. Responses were equal or superior to that
induced by previous treatment schedules in 69% of patients. The PR
(59% vs 66%) and VGPR (18% vs 28%) rates were similar between
patients who received or not prior Bortezomib regimens. Similarly, the
PR (67% vs 69%) and VGPR (27% vs 19%) rates were analogous
between patients who received prior Thalidomide regimens or those
who did not. From the start of PAD therapy, the 1-year progression free
survival (PFS) and the 1-year overall survival (OS) were 34% and 67%,
respectively. Patients treated with PAD as 2nd line, showed a 1-year PFS
of 57%. The 1-year PFS was not different between patients who received
prior Bortezomib based-regimens and those who did not (16% vs 39%,
p